Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study:



Publication date: May 2020

Source: European Journal of Cancer, Volume 131

Author(s): Alexis B. Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlesi, Gérard Zalcman, Patrick Dumont, Damien Pouessel, Claire Poulet, Clara Fontaine-Delaruelle, Sandrine Hiret, Adrien Dixmier, Patrick-Aldo Renault, Catherine Becht, Olivier Raffy, Charles Dayen, Julien Mazieres, Eric Pichon, Alexandra Langlais, Franck Morin